---
title: "Novartis partners with Asieris to bet on cardiovascular asset, with a total transaction amount of up to 5.2 billion USD"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255808830.md"
description: "Swiss pharmaceutical giant Novartis has reached a collaboration with Chinese biotechnology company Asieris, signing a multi-asset licensing and option agreement with a total transaction value of up to $5.2 billion. Novartis will obtain the rights to develop and commercialize two drugs and will have the right of first negotiation after Asieris completes clinical trials. Asieris will receive a $160 million upfront payment and subsequent milestone payments, with future opportunities for sales sharing and equity financing support"
datetime: "2025-09-03T13:42:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255808830.md)
  - [en](https://longbridge.com/en/news/255808830.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255808830.md)
generator: "portal-rs"
---

# Novartis partners with Asieris to bet on cardiovascular asset, with a total transaction amount of up to 5.2 billion USD

According to the Zhitong Finance APP, Swiss pharmaceutical giant Novartis (NVS.US) has announced an expansion of its cooperation with Chinese biotechnology company Asieris. The two parties have signed a multi-asset licensing and option agreement for several cardiovascular assets, with a total transaction amount of up to $5.2 billion.

Under the cooperation terms announced on Wednesday, Novartis will receive two licensing options: for two candidate molecules in the drug discovery phase, aimed at treating severe hypertriglyceridemia (sHTG) and mixed dyslipidemia, Novartis can choose to acquire the development and commercialization rights for these molecules in markets outside of China.

Additionally, after Asieris completes a joint clinical trial of the candidate drug BW-00112 (a Phase II asset targeting angiopoietin-like protein 3 (ANGPTL3) for the treatment of dyslipidemia), Novartis will have the right of first negotiation for this drug. The scope of this licensing cooperation also includes another candidate molecule from Asieris that is currently in the early research stage and based on RNA technology.

The agreement terms indicate that Asieris will receive a $160 million upfront payment from Novartis; in addition, if subsequent research, registration, and commercialization milestones are achieved as agreed, Asieris could receive milestone payments and option exercise payments totaling up to $5.2 billion.

At the same time, Asieris will also have the right to receive sales royalties based on the commercialization performance of the cooperative assets; in future financing rounds, Asieris will also be eligible for potential equity financing support from Novartis

### Related Stocks

- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)
- [688176.CN](https://longbridge.com/en/quote/688176.CN.md)

## Related News & Research

- [Kynexis extends Series A to EUR 97 million, Novartis Venture Fund joins round led by Forbion](https://longbridge.com/en/news/296347495.md)
- [Nuvation Bio (NUVB) Gains Fast Track Backing As Fair Value Stays In Focus](https://longbridge.com/en/news/296701962.md)
- [Boehringer again rises up rare disease reputation rankings](https://longbridge.com/en/news/296577935.md)
- [Great Lakes Advisors LLC Acquires Shares of 29,800 Supernus Pharmaceuticals, Inc. $SUPN](https://longbridge.com/en/news/296676820.md)
- [Callan Family Office LLC Buys New Position in Vertex Pharmaceuticals Incorporated $VRTX](https://longbridge.com/en/news/296677120.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**